MANNKIND CORP (MNKD) Stock Fundamental Analysis
NASDAQ:MNKD - Nasdaq - US56400P7069 - Common Stock - Currency: USD
Taking everything into account, MNKD scores 5 out of 10 in our fundamental rating. MNKD was compared to 557 industry peers in the Biotechnology industry. MNKD has only an average score on both its financial health and profitability. MNKD is growing strongly while it also seems undervalued. This is an interesting combination
1. Profitability
1.1 Basic Checks
MNKD had positive earnings in the past year.
MNKD had a positive operating cash flow in the past year.
MNKD had negative earnings in 4 of the past 5 years.
In multiple years MNKD reported negative operating cash flow during the last 5 years.
1.2 Ratios
With an excellent Return On Assets value of 7.23%, MNKD belongs to the best of the industry, outperforming 93.18% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 22.19%, MNKD belongs to the top of the industry, outperforming 98.03% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.23% | ||
| ROE | N/A | ||
| ROIC | 22.19% |
ROA(3y)-8.37%
ROA(5y)-20.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of MNKD (9.96%) is better than 93.00% of its industry peers.
MNKD has a better Operating Margin (27.25%) than 97.31% of its industry peers.
MNKD's Gross Margin of 75.77% is amongst the best of the industry. MNKD outperforms 83.66% of its industry peers.
In the last couple of years the Gross Margin of MNKD has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.25% | ||
| PM (TTM) | 9.96% | ||
| GM | 75.77% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.44%
GM growth 5Y5.99%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so MNKD is creating value.
MNKD has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, MNKD has more shares outstanding
Compared to 1 year ago, MNKD has an improved debt to assets ratio.
2.2 Solvency
MNKD has an Altman-Z score of -7.56. This is a bad value and indicates that MNKD is not financially healthy and even has some risk of bankruptcy.
MNKD has a Altman-Z score of -7.56. This is in the lower half of the industry: MNKD underperforms 69.48% of its industry peers.
The Debt to FCF ratio of MNKD is 13.30, which is on the high side as it means it would take MNKD, 13.30 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of MNKD (13.30) is better than 91.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 13.3 | ||
| Altman-Z | -7.56 |
ROIC/WACC2.89
WACC7.69%
2.3 Liquidity
MNKD has a Current Ratio of 2.36. This indicates that MNKD is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of MNKD (2.36) is worse than 71.27% of its industry peers.
MNKD has a Quick Ratio of 2.11. This indicates that MNKD is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.11, MNKD is not doing good in the industry: 72.89% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.36 | ||
| Quick Ratio | 2.11 |
3. Growth
3.1 Past
MNKD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 166.67%, which is quite impressive.
The Revenue has grown by 32.48% in the past year. This is a very strong growth!
MNKD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 35.29% yearly.
EPS 1Y (TTM)166.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)32.48%
Revenue growth 3Y55.86%
Revenue growth 5Y35.29%
Sales Q2Q%18.25%
3.2 Future
The Earnings Per Share is expected to grow by 43.66% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 14.59% on average over the next years. This is quite good.
EPS Next Y129.5%
EPS Next 2Y77%
EPS Next 3Y57.82%
EPS Next 5Y43.66%
Revenue Next Year14.79%
Revenue Next 2Y14.16%
Revenue Next 3Y13.13%
Revenue Next 5Y14.59%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 47.13, the valuation of MNKD can be described as expensive.
Compared to the rest of the industry, the Price/Earnings ratio of MNKD indicates a rather cheap valuation: MNKD is cheaper than 92.10% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 26.35. MNKD is valued rather expensively when compared to this.
With a Price/Forward Earnings ratio of 15.04, MNKD is valued correctly.
Based on the Price/Forward Earnings ratio, MNKD is valued cheaply inside the industry as 94.08% of the companies are valued more expensively.
MNKD's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.19.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 47.13 | ||
| Fwd PE | 15.04 |
4.2 Price Multiples
95.87% of the companies in the same industry are more expensive than MNKD, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, MNKD is valued cheaply inside the industry as 92.46% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 52.52 | ||
| EV/EBITDA | 12.29 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MNKD's earnings are expected to grow with 57.82% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.36
PEG (5Y)N/A
EPS Next 2Y77%
EPS Next 3Y57.82%
5. Dividend
5.1 Amount
No dividends for MNKD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
3.77
-0.04 (-1.05%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners58.52%
Inst Owner Change6.07%
Ins Owners1.61%
Ins Owner Change6.26%
Market Cap1.15B
Analysts86.15
Price Target10.49 (178.25%)
Short Float %8.32%
Short Ratio11.97
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-14.59%
Min EPS beat(2)-18.3%
Max EPS beat(2)-10.87%
EPS beat(4)0
Avg EPS beat(4)-77.7%
Min EPS beat(4)-246.98%
Max EPS beat(4)-10.87%
EPS beat(8)3
Avg EPS beat(8)-19.02%
EPS beat(12)5
Avg EPS beat(12)-10.38%
EPS beat(16)6
Avg EPS beat(16)-8.65%
Revenue beat(2)2
Avg Revenue beat(2)0.64%
Min Revenue beat(2)0.38%
Max Revenue beat(2)0.9%
Revenue beat(4)3
Avg Revenue beat(4)0.75%
Min Revenue beat(4)-7.78%
Max Revenue beat(4)9.49%
Revenue beat(8)6
Avg Revenue beat(8)3.43%
Revenue beat(12)9
Avg Revenue beat(12)6.54%
Revenue beat(16)12
Avg Revenue beat(16)6.34%
PT rev (1m)0%
PT rev (3m)2.86%
EPS NQ rev (1m)12%
EPS NQ rev (3m)16.68%
EPS NY rev (1m)0%
EPS NY rev (3m)-26.53%
Revenue NQ rev (1m)-1.64%
Revenue NQ rev (3m)-3.09%
Revenue NY rev (1m)0.89%
Revenue NY rev (3m)0.63%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 47.13 | ||
| Fwd PE | 15.04 | ||
| P/S | 3.85 | ||
| P/FCF | 52.52 | ||
| P/OCF | 38.93 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 12.29 |
EPS(TTM)0.08
EY2.12%
EPS(NY)0.25
Fwd EY6.65%
FCF(TTM)0.07
FCFY1.9%
OCF(TTM)0.1
OCFY2.57%
SpS0.98
BVpS-0.19
TBVpS-0.22
PEG (NY)0.36
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.23% | ||
| ROE | N/A | ||
| ROCE | 27.56% | ||
| ROIC | 22.19% | ||
| ROICexc | 49.27% | ||
| ROICexgc | 51.75% | ||
| OM | 27.25% | ||
| PM (TTM) | 9.96% | ||
| GM | 75.77% | ||
| FCFM | 7.33% |
ROA(3y)-8.37%
ROA(5y)-20.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.44%
GM growth 5Y5.99%
F-Score7
Asset Turnover0.73
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 13.3 | ||
| Debt/EBITDA | 3 | ||
| Cap/Depr | 93.83% | ||
| Cap/Sales | 2.56% | ||
| Interest Coverage | 5.56 | ||
| Cash Conversion | 33% | ||
| Profit Quality | 73.61% | ||
| Current Ratio | 2.36 | ||
| Quick Ratio | 2.11 | ||
| Altman-Z | -7.56 |
F-Score7
WACC7.69%
ROIC/WACC2.89
Cap/Depr(3y)397.13%
Cap/Depr(5y)337.1%
Cap/Sales(3y)10.78%
Cap/Sales(5y)10.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)166.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y129.5%
EPS Next 2Y77%
EPS Next 3Y57.82%
EPS Next 5Y43.66%
Revenue 1Y (TTM)32.48%
Revenue growth 3Y55.86%
Revenue growth 5Y35.29%
Sales Q2Q%18.25%
Revenue Next Year14.79%
Revenue Next 2Y14.16%
Revenue Next 3Y13.13%
Revenue Next 5Y14.59%
EBIT growth 1Y161.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y130.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y148.04%
OCF growth 3YN/A
OCF growth 5YN/A